1. Home
  2. LMAT vs NTLA Comparison

LMAT vs NTLA Comparison

Compare LMAT & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LMAT
  • NTLA
  • Stock Information
  • Founded
  • LMAT 1983
  • NTLA 2014
  • Country
  • LMAT United States
  • NTLA United States
  • Employees
  • LMAT N/A
  • NTLA N/A
  • Industry
  • LMAT Medical/Dental Instruments
  • NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • Sector
  • LMAT Health Care
  • NTLA Health Care
  • Exchange
  • LMAT Nasdaq
  • NTLA Nasdaq
  • Market Cap
  • LMAT 2.0B
  • NTLA 1.4B
  • IPO Year
  • LMAT 2006
  • NTLA 2016
  • Fundamental
  • Price
  • LMAT $94.88
  • NTLA $14.81
  • Analyst Decision
  • LMAT Buy
  • NTLA Buy
  • Analyst Count
  • LMAT 7
  • NTLA 17
  • Target Price
  • LMAT $92.83
  • NTLA $58.63
  • AVG Volume (30 Days)
  • LMAT 107.5K
  • NTLA 2.7M
  • Earning Date
  • LMAT 10-31-2024
  • NTLA 11-07-2024
  • Dividend Yield
  • LMAT 0.66%
  • NTLA N/A
  • EPS Growth
  • LMAT 49.21
  • NTLA N/A
  • EPS
  • LMAT 1.82
  • NTLA N/A
  • Revenue
  • LMAT $213,029,000.00
  • NTLA $45,967,000.00
  • Revenue This Year
  • LMAT $15.01
  • NTLA $51.43
  • Revenue Next Year
  • LMAT $9.07
  • NTLA $11.32
  • P/E Ratio
  • LMAT $48.54
  • NTLA N/A
  • Revenue Growth
  • LMAT 14.81
  • NTLA N/A
  • 52 Week Low
  • LMAT $47.33
  • NTLA $13.95
  • 52 Week High
  • LMAT $101.67
  • NTLA $34.87
  • Technical
  • Relative Strength Index (RSI)
  • LMAT 62.88
  • NTLA 31.64
  • Support Level
  • LMAT $86.62
  • NTLA $13.95
  • Resistance Level
  • LMAT $90.82
  • NTLA $16.98
  • Average True Range (ATR)
  • LMAT 2.83
  • NTLA 1.04
  • MACD
  • LMAT 0.31
  • NTLA -0.46
  • Stochastic Oscillator
  • LMAT 60.01
  • NTLA 11.44

About LMAT LeMaitre Vascular Inc.

LeMaitre Vascular Inc manufactures and distributes medical devices for the treatment of peripheral vascular disease. Its products are used during open vascular surgery and address several anatomical areas, such as the carotid, lower extremities, upper extremities, and aorta. The firm's lower extremities product line contributes towards the proportion of revenue, followed by the carotid product line. LeMaitre's surgical devices include angioscopes, balloon catheters, carotid shunts, phlebectomy devices, vascular grafts, vascular patches, and vessel closure systems. LeMaitre generates the majority of its revenue in the United States.

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Share on Social Networks: